Highlights
- RAD has received commitments for a placement of over 24 million shares under an entitlement offer shortfall.
- The amount raised through theentitlement offer shortfall will be approximately AU$1.7 million.
- The funds raised will support RAD’s clinical programs.
Radiopharm Theranostics Limited (ASX: RAD) has received commitments for nearly AU$1.7 million for a shortfall under an entitlement offer. The entitlement offer shortfall will entail the issue of 24,025,716 shares at an issue price AU$0.07 per share.
The funds raised will support the clinical programs of the company.
On 30 January 2024, the shares issued under shortfall will be settled and on 31 January 2024, shares are planned to be allotted.
About the entitlement offer
In October 2023, the company had announced a non-renounceable entitlement offer for one new RAD share for every 2.35 RAD shares held at AU$0.07 issue price.
Through the offer, the company raised nearly AU$2.1 million by issuing 30,197,244 shares. More.
RAD shares traded at AU$0.075 apiece at the time of writing on 24 January 2024.